ClinicalTrials.gov
ClinicalTrials.gov Menu

Short Term Effects of HMG-CoA Reductase Inhibition (Atorvastatin)on Renal Hemodynamics, Tubular Function and Vasoactive Hormones on Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00345202
Recruitment Status : Completed
First Posted : June 27, 2006
Last Update Posted : May 15, 2008
Sponsor:
Information provided by:
Regional Hospital Holstebro

Brief Summary:
We wanted to test the shortterm effects of HMG-CoA reductase inhibition (atorvastatin) on renal hemodynamics, renal tubular function and vasoactive hormones on healthy subjects.

Condition or disease Intervention/treatment Phase
Healthy Drug: HMG-CoA reductase inhibition (atorvastatin) Phase 4

Study Type : Interventional  (Clinical Trial)
Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Official Title: Short Term Effects of HMG-CoA Reductase Inhibition (Atorvastatin)on Renal Hemodynamics, Tubular Function and Vasoactive Hormones on Healthy Subjects.
Study Start Date : September 2004
Actual Primary Completion Date : February 2005
Actual Study Completion Date : February 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hormones




Primary Outcome Measures :
  1. GFR
  2. RPF
  3. FEna
  4. FELi
  5. CLna
  6. CLli


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Both men and women
  • Age: Between 20-50
  • BMI<30

Exclusion Criteria:

  • Cl. signs or history of disease of heart, lungs, kidneys or endocrine organs.
  • Abnormal lab. tests( haemoglobin, pl. sodium, pl. potassium, pl.creatinine, pl.bilirubin, pl.ALAT, pl. cholesterol, blood glucose)
  • Albuminuria or glucosuria
  • Cancer
  • Art. hypertension
  • Alcohol abuse
  • Med. treatment, except oral contraceptives
  • Pregnancy or breast feeding
  • Blood donation less than 1 month before study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00345202


Locations
Denmark
Medical research unit, Department of medicin, Holstebro Sygehus
Holstebro, Ringkøbing countie, Denmark, 7500
Sponsors and Collaborators
Regional Hospital Holstebro
Investigators
Study Chair: Erling B. Pedersen, Professor Holstebro Sygehus

ClinicalTrials.gov Identifier: NCT00345202     History of Changes
Other Study ID Numbers: MED.RES.HOS.2004.02.LP
First Posted: June 27, 2006    Key Record Dates
Last Update Posted: May 15, 2008
Last Verified: May 2008

Keywords provided by Regional Hospital Holstebro:
HMG-COA reductase inhibition
GFR
RPF
FE
CL

Additional relevant MeSH terms:
Hormones
Atorvastatin Calcium
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors